DDInter1263 DDInter1840
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Naltrexone {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Bosutinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Bosutinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone {u} (Compound) upregulates {v} (Gene) TCTA
TCTA {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Naltrexone {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Naltrexone (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Naltrexone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Naltrexone (Compound) upregulates TCTA (Gene) and TCTA (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Naltrexone (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)